MCID: PRS126
MIFTS: 32

Prostate Cancer Susceptibility

Categories: Genetic diseases, Cancer diseases

Aliases & Classifications for Prostate Cancer Susceptibility

MalaCards integrated aliases for Prostate Cancer Susceptibility:

Name: Prostate Cancer Susceptibility 24

Classifications:



Summaries for Prostate Cancer Susceptibility

MalaCards based summary : Prostate Cancer Susceptibility is related to prostate cancer and splenic infarction. An important gene associated with Prostate Cancer Susceptibility is AR (Androgen Receptor), and among its related pathways/superpathways are Pathways in cancer and Integrated Breast Cancer Pathway. The drugs Selenium and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and heart, and related phenotypes are endocrine/exocrine gland and neoplasm

Related Diseases for Prostate Cancer Susceptibility

Graphical network of the top 20 diseases related to Prostate Cancer Susceptibility:



Diseases related to Prostate Cancer Susceptibility

Symptoms & Phenotypes for Prostate Cancer Susceptibility

MGI Mouse Phenotypes related to Prostate Cancer Susceptibility:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.65 AR BRCA2 CDH1 CHEK2 HNF1B HOXB13
2 neoplasm MP:0002006 9.1 AR BRCA2 CDH1 CHEK2 MSMB ZFHX3

Drugs & Therapeutics for Prostate Cancer Susceptibility

Drugs for Prostate Cancer Susceptibility (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Vet_approved Phase 1 7782-49-2
2
Metronidazole Approved Phase 1 443-48-1 4173
3
Lenograstim Approved Phase 1 135968-09-1
4
Docetaxel Approved May 1996, Investigational Phase 1 114977-28-5 148124 9877265
5 Antioxidants Phase 1
6 Micronutrients Phase 1
7 Protective Agents Phase 1
8 Trace Elements Phase 1
9 Androgens Phase 1
10 Anti-Infective Agents Phase 1
11 Antiparasitic Agents Phase 1
12 Antiprotozoal Agents Phase 1
13 Hormone Antagonists Phase 1
14 Hormones Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
16 Vaccines Phase 1
17 Adjuvants, Immunologic Phase 1
18 Antimitotic Agents Phase 1
19
Dexmedetomidine Approved, Vet_approved 76631-46-4, 113775-47-6 68602 5311068 56032
20 Pharmaceutical Solutions
21 Adrenergic Agents
22 Adrenergic Agonists
23 Adrenergic alpha-2 Receptor Agonists
24 Adrenergic alpha-Agonists
25 Analgesics
26 Analgesics, Non-Narcotic
27 Anesthetics
28 Central Nervous System Depressants
29 Hypnotics and Sedatives
30 Neurotransmitter Agents
31 Peripheral Nervous System Agents
32
Abiraterone acetate 154229-18-2 57336518
33 Cytochrome P-450 Enzyme Inhibitors
34 Steroid Synthesis Inhibitors
35 Cola Nutraceutical

Interventional clinical trials:

(show all 24)

id Name Status NCT ID Phase Drugs
1 Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer Completed NCT00217516 Phase 1 selenium
2 A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy Completed NCT00096551 Phase 1 Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM);Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM);Recombinant Fowlpox-GM-CSF
3 Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer Active, not recruiting NCT02478125 Phase 1 Burixafor Hydrobromide;Docetaxel;G-CSF
4 An Exploration of Genetic Testing for Prostate Cancer Susceptibility Unknown status NCT00997464
5 Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome Unknown status NCT00167024
6 Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00758173
7 Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives Unknown status NCT01013129
8 Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer Unknown status NCT00959023
9 Epidemiologic and Genetic Study on Familial Prostate Cancer Unknown status NCT01221168
10 Identification of Prostate Cancer Genes Completed NCT00342784
11 Genetic Analysis of Hereditary Prostate Cancer Completed NCT00001469
12 Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer Completed NCT00003329
13 Magnetic Resonance (MR) Spectroscopy in Localized Prostate Cancer Completed NCT00756392
14 Identifying Prostate Brachytherapy Seeds Using MRI Completed NCT01878058
15 Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial- Completed NCT02536014 Dexmedetomidine;Saline
16 Physicians Survey on Genetic Testing Completed NCT00341107
17 Prostate Cancer Screening Among Men With High Risk Genetic Predisposition Recruiting NCT02053805
18 The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer Recruiting NCT00261456
19 Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations Recruiting NCT02705846
20 Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Recruiting NCT00579514
21 Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer Recruiting NCT00050752
22 Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate Recruiting NCT01858441 Abiraterone Acetate
23 The BARCODE 1 Study Recruiting NCT03158922
24 Imaging of High Grade Prostate Cancer Terminated NCT02177526

Search NIH Clinical Center for Prostate Cancer Susceptibility

Genetic Tests for Prostate Cancer Susceptibility

Genetic tests related to Prostate Cancer Susceptibility:

id Genetic test Affiliating Genes
1 Prostate Cancer Susceptibility 24 AR BRCA2 CDH1 CHEK2 ZFHX3 HOXB13 ELAC2

Anatomical Context for Prostate Cancer Susceptibility

MalaCards organs/tissues related to Prostate Cancer Susceptibility:

39
Prostate, Testes, Heart

Publications for Prostate Cancer Susceptibility

Articles related to Prostate Cancer Susceptibility:

(show top 50) (show all 129)
id Title Authors Year
1
Association of estrogen receptor I+ PvuII and XbaI polymorphisms with prostate cancer susceptibility and risk stratification: a meta-analysis from case-control studies. ( 28721070 )
2017
2
Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men. ( 28543179 )
2017
3
Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects. ( 28445160 )
2017
4
Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. ( 26823525 )
2016
5
A comprehensive analysis of genome-wide association studies to identify prostate cancer susceptibility loci for the Romanian population. ( 27516020 )
2016
6
Association between manganese superoxide dismutase (MnSOD) polymorphism and prostate cancer susceptibility: a meta-analysis. ( 27055786 )
2016
7
Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis. ( 27553621 )
2016
8
Genetic variants in insulin-like growth factor binding protein-3 are associated with prostate cancer susceptibility in Eastern Chinese Han men. ( 26730204 )
2016
9
Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies. ( 27524905 )
2016
10
MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai. ( 27819322 )
2016
11
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. ( 26964030 )
2016
12
Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis. ( 27626483 )
2016
13
Gene regulatory mechanisms underpinning prostate cancer susceptibility. ( 26950096 )
2016
14
Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes. ( 27902461 )
2016
15
Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility. ( 27706719 )
2016
16
Association between LAPTM4B gene polymorphism and prostate cancer susceptibility in an Iranian population. ( 28090574 )
2016
17
Association of three 8q24 polymorphisms with prostate cancer susceptibility: evidence from a meta-analysis with 50,854 subjects. ( 26159557 )
2015
18
Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer. ( 26074659 )
2015
19
Association between EHBP1 rs721048(A>G) polymorphism and prostate cancer susceptibility: a meta-analysis of 17 studies involving 150,678 subjects. ( 26185455 )
2015
20
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. ( 25837820 )
2015
21
Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. ( 26130958 )
2015
22
Correction: The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. ( 26429985 )
2015
23
Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11. ( 26347821 )
2015
24
The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case-control studies. ( 25234162 )
2015
25
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. ( 26162851 )
2015
26
Association of glutathione S-transferase T1 and M1 polymorphisms with prostate cancer susceptibility in populations of Asian descent: a meta-analysis. ( 26416453 )
2015
27
Correction: A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes. ( 25933217 )
2015
28
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. ( 26025378 )
2015
29
Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis. ( 25085585 )
2014
30
The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. ( 25274378 )
2014
31
Network-based approach reveals Y chromosome influences prostate cancer susceptibility. ( 25199846 )
2014
32
An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. ( 24581739 )
2014
33
A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. ( 24390282 )
2014
34
A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. ( 25411967 )
2014
35
GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. ( 23979608 )
2013
36
Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. ( 23883402 )
2013
37
MNS16A tandem repeat minisatellite of human telomerase gene and prostate cancer susceptibility. ( 23423318 )
2013
38
Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. ( 23833122 )
2013
39
CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. ( 23475304 )
2013
40
Association of prostate cancer susceptibility variant (MSMB) rs10993994 with risk of spermatogenic failure. ( 23608167 )
2013
41
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. ( 23535732 )
2013
42
Lack of association between COMT Val158Met polymorphism and prostate cancer susceptibility. ( 23257985 )
2013
43
Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. ( 23872201 )
2013
44
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. ( 23065704 )
2013
45
Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. ( 22782870 )
2013
46
N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients. ( 22246524 )
2012
47
Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. ( 22374248 )
2012
48
IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. ( 22323358 )
2012
49
The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. ( 21515665 )
2012
50
Lack of association of CYP1A1 polymorphism with prostate cancer susceptibility of Tunisian men. ( 22304463 )
2012

Variations for Prostate Cancer Susceptibility

ClinVar genetic disease variations for Prostate Cancer Susceptibility:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 AR NM_000044.4(AR): c.2180G> T (p.Arg727Leu) single nucleotide variant Pathogenic rs137852593 GRCh37 Chromosome X, 66937326: 66937326
2 HOXB13 NM_006361.5(HOXB13): c.251G> A (p.Gly84Glu) single nucleotide variant Pathogenic,risk factor rs138213197 GRCh37 Chromosome 17, 46805705: 46805705

Expression for Prostate Cancer Susceptibility

Search GEO for disease gene expression data for Prostate Cancer Susceptibility.

Pathways for Prostate Cancer Susceptibility

Pathways related to Prostate Cancer Susceptibility according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.15 AR BRCA2 CDH1 CTBP2 KLK3
2 11.11 AR BRCA2 CDH1 CHEK2
3 10.83 AR HOXB13 KLK3

GO Terms for Prostate Cancer Susceptibility

Biological processes related to Prostate Cancer Susceptibility according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.35 AR DAB2IP HNF1B JAZF1 ZFHX3
2 cellular protein catabolic process GO:0044257 9.32 CHEK2 DAB2IP
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 BRCA2 CHEK2
4 positive regulation of transcription, DNA-templated GO:0045893 9.1 AR BRCA2 CDH1 CHEK2 HNF1B ZFHX3
5 prostate gland development GO:0030850 8.96 AR

Sources for Prostate Cancer Susceptibility

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....